Crohn’s Disease
Crohn’s disease is an inflammatory disease involving intestinal pain, diarrhea, and malabsorption of nutrients. The disease is characterized by periods of active disease interspersed with periods of remission. Elemental diet (ED) therapy is the preferred treatment in Japan. Conventional treatment with prednisone and salycylates has been only marginally successful in extending the periods of remission. The ED therapy involves tube feeding (enteral nutrition) a mixture of free amino acids, short-chain maltodextrins, and low levels of fat in the form of soybean oil. Not surprisingly, compliance with this diet is poor resulting in shorter periods of remission.
Researchers at the University of Bologna report that fish oils can prevent relapses. Their experiment involved 78 patients with Crohn’s disease who had been classified as having a high risk of relapse. Half the patients were randomized to receive nine fish oil capsules daily, the other half received nine placebo capsules daily. The fish oil capsules contained 500 mg of a marine lipid concentrate each (40 per cent eicosapentaenoic acid and 20 per cent docosahexaenoic acid) and provided a total of 2.7 grams of n-3 fatty acids per day. The capsules were enteric-coated so as to ensure that they dissolved in the small intestine instead of in the stomach and to minimize unpleasant side effects such as flatulence, heartburn, belching, and diarrhea. The results of the fish oil therapy were spectacular. While 69% of the patients in the control group had a relapse during the one-year study period, only 28% in the therapy group did. At the end of the one-year period 59% of the patients in the fish oil group were still in remission as compared to only 26% in the placebo group. The researchers conclude that fish oil therapy (with enteric-coated capsules) is effective in preventing relapses in patients with Crohn’s disease in remission.
Tags: Crohn's Disease, omega 3, Seal Oil
Cardiovascular Disorders
Since 1990, researchers from the Louisiana State University have analyzed the coronary arteries of 23,000 deceased persons from 16 countries. The interim results reveal that the Greenlanders have the lowest rate of arteriosclerosis among all those tested.
Some of the fascinating early results are as follows:
1) The Inuit who ate a modern diet had the same rate of this disease as ordinary Europeans and therefore the results were not based on heredity.
2) The Inuit who lived on a traditional diet of marine mammals (mainly seal) had, at the age of seventy, the same coronary artery elasticity as a 20 year old European.
3) Some European countries may eat more fish than is found in the traditional Greenland diet, but have a far higher incidence of arteriosclerosis and, in general, higher levels of cholesterol.
At the National Hospital in Nuuk, a person with very high cholesterol was given various diets and medicines without major impact. When he was placed on a traditional Greenland diet (mostly of seal), his cholesterol level fell dramatically in one month.
The Orsoq Study
Dr. E. Jorgenson of the Center of Arctic Environmental Medicine in Denmark recently presented the initial results of the Orsoq Seal Research Project, a pilot study on the effect of seal oil on human health. These preliminary findings indicate that the general population of Denmark, fed on a modern diet, was ten times more likely to develop cardiovascular and inflammatory diseases that Greenlanders on their traditional diet of seal, a food high in omega 3
“Inuit Whaling”, Inuit Circumpolar Conference, June 1992, special issue. Gerth Mulved and Henning Sloth Pederson, Doctors of Medicine Dronning Ingrids Hospital.
Numerous studies show that increased long term intake of marine oils, rich in EPA and DHA, reduces the morbidity and mortality associated with cardiovascular disorders in middle-aged men. Conflicting data exist as to whether it is EPA or DHA, or the combination which is responsible for the various beneficial effects. In any event, it is known that there may be limits to the elongation and desaturation of EPA to DHA, whereas the retroconversion of DHA to EPA occurs.
-Harris et al., Grimsgaard et al., 1995
It is generally agreed that omega-3 fatty acids moderate hyperlipidemia, particularly hypertriglyceridemia, very rapidly in a dose dependent manner. Omega-3 fatty acids reduce the triglyceride levels in the blood by a reduced synthesis and secretion of VLDL particles from the liver and enhances the in vivo liposysis of the VLDL-particles. An improved balance between LDL-cholesterol and HDL-cholesterol is also normally found, whereas the effect on total cholesterol is marginal. A large number of studies report such findings. Omega-3 fatty acids influence on platelet aggregability at rather low doses (50-350mg), whereas significant effects on blood lipids and blood pressure can be achieved at higher doses (2 g/day).
-Christensen et al, 1995
Recent data (from a parallel group study) show that 3g pure DHA (95% DHA, ethyl ester) produce a 30-40% greater reduction in triglyceride levels in plasma than a corresponding amount of EPA (90% EPA, ethyl ester). DHA also seems to have a more marked effect on increasing HDL-cholesterol, whereas EPA was found to slightly decrease both total cholesterol and APO-1 in normal subjects
-Grimsgaard et al, 1995.
This study suggests that DHA might be more beneficial than EPA in terms of effects on blood lipids. Others have reported that DHA-rich oils (4g/day, 42% DHA) are less active than EPA-rich oils and fish diet on both fasting and postprandial triglyceride levels.
-Argen, 1995
A positive correlation has been observed between supplementation with EPA and DHA (85% ethyl ester) and improvements in blood pressure and heart rate in subjects suffering from mild hypertension. Recently published studies showed that DHA (EE), not EPA (EE), lowered the heart rate in healthy humans.
-Bönaa el al, 1995
Even short time supplementation with large amounts (19g/day) of a combination of EPA and DHA (as ethyl esters) has shown to have long-lasting effects on the human platelet aggregation, an effect suggested by inhibition on TXA2/PGH2 receptor by EPA and/or DHA-sensitive mechanisms.
-Di Minno et al,1995
Studies on cardiac arrhythmias do not give any clear evidence on the efficacy of omega-3 fatty acids. However, a trend towards reduction in ventricular extracystoles in patients with ventricular tachyarrhythmias has been observed after supplementation with omega-3 fatty acids
-Christiansen et al,1995.
Animal studies show that DHA may inhibit ventricular tachyarrhytmias more significantly than EPA
-Leaf, 1995,
and also increases the cardiac contractibility.
-Grynberg et al, 1995
Recent data also show that DHA has more pronounced inhibitory effect on the expression of cytokines in endothelial cells, which clearly downregulate the inflammatory process and may inhibit the progression of arteriosclerosis.
-DeCaterina & Libby, 1995
Epidemiological and clinical research have shown that omega-3 fatty acids intervene in the arteriosclerotic process at all steps, and that there probably are synergistic effects of EPA and DHA at many levels.
-Argen,1995
Tags: Cardiovascular Disorders, omega 3, Seal Oil
